Huntington's disease nursing: reference guide for students

Huntington’s disease (HD) is a hereditary, progressive neurodegenerative disorder caused by an abnormal CAG repeat expansion in the HTT gene on chromosome 4. It produces a characteristic clinical triad of involuntary choreiform movements, cognitive decline, and psychiatric disturbance — most often emerging between ages 30 and 50. There is no disease-modifying treatment; every intervention targets symptoms and quality of life. For nursing students, HD is high-yield because it integrates genetics, neurological assessment, psychiatric nursing, nutritional management, swallowing safety, and end-of-life care into a single condition. This reference covers pathophysiology, clinical presentation, diagnostics, nursing assessment, nursing interventions, pharmacology, complications, NCLEX-focused clinical reasoning patterns, and priority nursing diagnoses.

Quick reference: HD at a glance

Pathophysiology

CAG repeat expansion

Huntington’s disease is caused by an expansion of a cytosine-adenine-guanine (CAG) trinucleotide repeat within exon 1 of the HTT gene on the short arm of chromosome 4. In healthy individuals, the CAG sequence repeats between 10 and 35 times. A repeat count of 36 or more is sufficient to produce abnormal huntingtin protein, with full penetrance at 40 or more repeats. Repeats of 36–39 show reduced penetrance — meaning not all individuals in this range develop the disease, and onset may occur later in life.

Anticipation is the phenomenon in which HD can present earlier and progress more rapidly in successive generations. This occurs because CAG repeats tend to expand during spermatogenesis, making paternal transmission the primary driver of anticipation. This is particularly relevant for juvenile HD — most cases of onset before age 20 are inherited from an affected father.

Mutant huntingtin protein and striatal degeneration

The expanded CAG repeat encodes an abnormally long polyglutamine tract in the huntingtin protein. This mutant protein misfolds, aggregates, and disrupts multiple cellular processes: impaired transcription factor activity, mitochondrial dysfunction, defective axonal transport, and failure of normal protein degradation pathways. The resulting intranuclear and intracytoplasmic aggregates are toxic to neurons.

The striatum — specifically the caudate nucleus and putamen — is the earliest and most severely affected brain region. Medium spiny neurons of the striatum, which use gamma-aminobutyric acid (GABA) as their primary neurotransmitter, degenerate preferentially. These neurons project via the indirect pathway to inhibit the thalamus; when they are lost, the net effect is dopaminergic overactivity relative to GABAergic inhibition, producing the hyperkinetic movements (chorea) characteristic of early and middle HD.

As neurodegeneration progresses, the direct pathway neurons and cortical neurons are also lost, eventually producing bradykinesia and rigidity that can dominate the late stage. This late-stage motor profile is more similar to Parkinson’s disease — which features dopaminergic deficiency and rigidity — than to the hyperkinetic early HD phenotype.

Neurochemical imbalance

In early HD, the dominant imbalance is excess dopaminergic activity relative to depleted GABAergic inhibition in the striatum. This is why dopamine-depleting agents (tetrabenazine, deutetrabenazine) are the primary pharmacological approach to chorea. As the disease progresses, widespread cortical and subcortical atrophy develops, producing cognitive decline, personality changes, and eventual dementia.

Clinical presentation

The triad

HD produces three major symptom domains, which typically appear in this sequence:

1. Psychiatric symptoms — often precede motor symptoms by 10–15 years. Depression is the most common, affecting 30–50% of HD patients at some point in their illness. Irritability, apathy, anxiety, OCD-like behaviors, and personality changes are also common.
2. Cognitive decline — executive dysfunction (impaired planning, judgment, multitasking, and impulse control) is affected earliest. Unlike Alzheimer’s disease, HD dementia spares recognition memory early and primarily affects retrieval and executive function. Personality changes and behavioral disinhibition often precede formal cognitive testing findings.
3. Motor symptoms — chorea is the hallmark. Patients initially present with subtle fidgetiness, impersistence of gaze, and clumsiness, which evolve into prominent involuntary jerking movements of the face, trunk, and extremities.

Chorea

Chorea refers to random, irregular, involuntary movements that flow from one body part to another. In HD, choreiform movements initially appear subtle — patients may appear restless, and family members may notice a “dancing” quality to their gait. Chorea worsens significantly with emotional stress and anxiety; a calm, low-stimulation environment is therefore both an assessment finding and a nursing intervention target.

Unlike the tremor of Parkinson’s disease (which is resting, “pill-rolling,” and asymmetric), HD chorea is action-accentuated, bilateral, and involves larger amplitude movements. Gait disturbance in HD has a characteristic “dancing” appearance; patients are at high risk of falls.

Disease staging

HD is commonly divided into three functional stages:

Early stage (years 1–8): Subtle chorea, personality changes, mild cognitive changes (especially executive function), maintained independence in ADLs. Patients often remain employed with accommodation.

Middle stage (years 9–16): Prominent chorea, increasing gait instability, dysphagia emerging, significant cognitive decline, increasing psychiatric morbidity. Progressive dependence in ADLs. Weight loss becomes prominent as caloric expenditure from hyperkinesis increases.

Late stage (years 17+): Severe motor impairment (chorea may decrease as bradykinesia and rigidity dominate), profound cognitive impairment, complete dependence in ADLs, severe dysphagia requiring PEG consideration, bedbound state. End-of-life planning becomes central nursing work — similar to late-stage ALS.

Juvenile HD (Westphal variant)

When HD onset occurs before age 20, the clinical picture differs substantially. Rigidity dominates over chorea — the classical hyperkinetic presentation is absent or minimal. Patients may present with behavioral changes, academic decline, seizures, and progressive rigidity. The NCLEX takeaway: juvenile HD is more rigid than choreic, and most cases are paternally inherited (paternal anticipation via spermatogenesis).

Diagnostic criteria

Genetic testing

Genetic testing by PCR analysis of CAG repeat length in the HTT gene is definitive. A result of 36 or more CAG repeats confirms HD in a clinically symptomatic individual. The test is also used for:

• Diagnostic testing — in symptomatic individuals, to confirm the clinical diagnosis
• Predictive (presymptomatic) testing — in at-risk asymptomatic individuals who have a parent with confirmed HD

Predictive testing is an ethical minefield. The HDSA (Huntington’s Disease Society of America) protocol requires pre-test genetic counseling (to ensure the individual understands implications), post-test counseling (to support adaptation to results), and a waiting period — typically several weeks — between the initial consultation and sample collection. An individual may choose not to know their genetic status, and this choice must be respected. Predictive testing of minors is generally not performed because they cannot provide informed consent and cannot yet act on the information. Nursing students must understand that predictive testing requires pre-test AND post-test counseling — not merely informed consent.

Neuroimaging

Brain MRI typically shows caudate nucleus atrophy — the most characteristic finding. The caudate normally bulges into the lateral ventricles; its atrophy causes characteristic “box-car” enlargement of the lateral ventricles on axial views. Cortical atrophy progresses over time. MRI is used to support the diagnosis and to exclude other causes, but genetic testing is confirmatory.

UHDRS

The Unified Huntington’s Disease Rating Scale (UHDRS) is the standardized clinical assessment tool for HD. It evaluates four domains:

• Motor — chorea, dystonia, gait, eye movements, dysarthria (scored 0–124)
• Cognitive — Symbol Digit Modalities Test, verbal fluency (SDMT, Stroop)
• Behavioral — psychiatric symptoms including depression, irritability, apathy, psychosis
• Functional capacity — Total Functional Capacity (TFC) scale, independence scale

The TFC subscale (0–13) is particularly important: it measures ability to perform work, handle finances, manage domestic chores, perform ADLs, and require care. Scores correlate with disease stage.

Nursing assessment

UHDRS domains in clinical practice

When assessing an HD patient, structure your evaluation around the UHDRS domains:

Motor assessment: Observe for chorea frequency, amplitude, and distribution. Note whether movements worsen with emotional distress or fatigue. Assess for dystonia (sustained muscle contractions producing abnormal postures), which can co-exist with chorea and cause pain. Evaluate gait, falls risk, balance (ask about recent falls or near-falls), and eye movement abnormalities (impaired saccades — the ability to rapidly shift gaze — are an early and specific sign).

Cognitive assessment: Screen with the Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE), recognizing that HD cognitive decline is primarily executive, not memory-based initially. Note difficulty with multi-step instructions, planning, and impulse control. Compare the Glasgow Coma Scale if acute change in level of consciousness is suspected — useful to distinguish delirium from HD progression.

Psychiatric screening: Screen systematically for depression (PHQ-9), suicidal ideation (direct questioning), irritability/aggression, apathy, and anxiety. Apathy is often confused with depression but is a distinct syndrome in HD — it is loss of motivation and initiative without the subjective distress of depression. Accurate distinction matters because they have different pharmacological approaches. Always assess suicide risk directly; HD patients have a 4–6× elevated suicide risk compared to the general population, with elevated risk particularly during the pre-symptomatic period after a positive predictive test result.

Dysphagia assessment: Dysphagia is a major complication of middle and late HD. Perform bedside swallowing assessment: evaluate the patient’s ability to manage thin liquids, solid food, and mixed consistencies. Look for coughing or choking during meals, increased meal time, and post-meal wet/gurgly voice quality. Referral to speech-language pathology (SLP) for formal swallowing evaluation and modified barium swallow study should occur at the first sign of swallowing difficulty. Aspiration precautions must be initiated promptly.

Falls risk: Conduct a formal falls risk assessment (e.g., Morse Fall Scale) at every encounter. Chorea produces unpredictable, sudden movements that impair balance and can precipitate falls even when the patient appears to be moving purposefully. Environmental modifications are the primary preventive strategy.

Nutrition and weight: Weigh patients at every visit. HD patients are frequently in a hypermetabolic state due to constant choreiform movement — caloric requirements may reach 3,000–5,000 kcal/day. Weight loss in HD is a composite of hypermetabolism, dysphagia, psychiatric symptoms reducing appetite, and difficulty with self-feeding.

Comprehensive head-to-toe assessment remains the foundation for identifying comorbidities and changes from baseline; the head-to-toe assessment framework applies fully to HD patients.

Nursing interventions

Safety and falls prevention

Fall prevention is a priority nursing intervention throughout the disease course. Interventions include:

• Remove furniture with sharp corners from the patient’s living and sleeping areas
• Pad bed rails and high-risk surfaces
• Provide wide-based assistive devices (rollator walkers with wide wheelbases are generally preferred over standard walkers, which patients may trip over)
• Non-slip footwear at all times
• Helmets for patients with frequent falls and high risk of head injury
• Teach patients and caregivers that chorea worsens with anxiety, stress, and stimulant medications — reducing emotional distress reduces fall risk
• Consult physical therapy for gait training and adaptive equipment selection

Nutrition and caloric needs

Address HD’s high caloric requirements aggressively. Interventions include:

• High-calorie, nutrient-dense foods and supplements (protein shakes, nut butters, avocado, full-fat dairy)
• Small, frequent meals to reduce fatigue from prolonged eating
• Occupational therapy for adaptive feeding equipment (weighted utensils reduce the effect of chorea on self-feeding, non-spill cups)
• Monitor weight at every visit — weight loss greater than 5% in one month is a red flag requiring escalation
• When dysphagia is present: implement SLP-recommended diet texture modifications (IDDSI framework), thickened liquids as indicated, and chin-tuck technique during swallowing
• Discuss PEG tube timing early — before the patient loses decisional capacity — and honor advance directives; PEG timing in HD mirrors considerations in ALS

Dysphagia and aspiration precautions

• Aspiration pneumonia is a leading cause of death in late HD
• Position patient upright (90°) for all meals and for at least 30 minutes afterward
• Supervise meals — do not leave the patient alone while eating
• Provide thickened liquids per SLP recommendation
• Encourage small bites and adequate time between swallows
• Teach chin-tuck technique (chin to chest during swallow directs the bolus away from the airway)
• Monitor for signs of aspiration pneumonia (fever, increased respiratory rate, change in sputum, hypoxia)
• Seizure risk exists in HD, particularly in juvenile HD — know your facility’s seizure nursing protocol

Psychiatric symptom management

Depression and suicide prevention: Assess at every encounter. Use a calm, therapeutic communication style. Antidepressants (SSRIs are first-line) are effective for HD-related depression. Provide consistent, non-judgmental emotional support. Refer to psychology or psychiatry for formal assessment and pharmacological management. Educate the family that suicide risk is elevated — particularly during the pre-symptomatic period after a positive genetic test result — and provide crisis resources (988 Suicide and Crisis Lifeline).

Irritability and aggression: Common in HD; can precede motor symptoms by years. Avoid confrontational interactions. Maintain routine and predictability — unpredictable environments trigger irritability. SSRIs and atypical antipsychotics (quetiapine, olanzapine) are used pharmacologically.

Apathy: Engage the patient in meaningful activities at appropriate cognitive and motor levels. Avoid labeling apathy as “not trying” — it is a neurobiological symptom, not willful disengagement.

Psychosis: Quetiapine and olanzapine are preferred antipsychotics in HD; typical antipsychotics (haloperidol) worsen motor symptoms in some patients and should generally be avoided.

Genetic counseling support

The nurse plays a critical role in supporting patients and families through the genetic counseling process:

• Assess the patient’s understanding of autosomal dominant inheritance (50% risk to each biological child)
• Clarify that predictive genetic testing requires formal pre-test and post-test counseling through a certified genetic counselor — not simply a physician order
• Respect the patient’s right not to know their genetic status; never coerce testing
• Support family members who are at-risk — acknowledge the psychological burden of living with 50% risk uncertainty
• Assist with referrals to genetic counseling services and HD support organizations (HDSA)
• Address reproductive decision-making questions with sensitivity; in vitro fertilization with preimplantation genetic testing (PGT) allows at-risk individuals to have unaffected biological children

Environmental and cognitive support

• Minimize environmental stimulation during acute care — chorea worsens with noise, emotional stress, and overstimulation; a calm, low-stimulation environment is a clinical intervention
• Simplify communication: use short sentences, allow processing time, confirm understanding
• Maintain consistent daily routines to reduce executive function demands
• Involve the patient in care decisions while they retain capacity; document advance directives early

End-of-life planning

Initiate advance care planning discussions in the early disease stage, when the patient has full decisional capacity. Topics include: goals of care, preferred place of death, PEG tube preference, ventilatory support preferences, and POLST/MOLST documentation. The predictable progression of HD makes early planning both ethically appropriate and clinically practical. Hospice eligibility is generally considered when TFC score drops to 0–3 and the patient is fully dependent. Caregiver burden in HD is among the highest of any neurological disease — support the caregiver as you support the patient.

Pharmacology

Complications

10 NCLEX tips for Huntington’s disease

1. Autosomal dominant means 50% risk — not 100%. Each child of an affected HD parent has a 50% chance of inheriting the expanded CAG repeat — not 25% (recessive) and not certainty (100%). The disorder is fully penetrant above 40 repeats, meaning everyone who inherits it will develop HD if they live long enough.

2. Tetrabenazine is contraindicated in untreated depression. Before initiating tetrabenazine or deutetrabenazine, screen for depression and suicidal ideation. These agents deplete monoamines — including serotonin and norepinephrine — and can precipitate or worsen depression. If depression is present, treat it adequately before starting VMAT2 inhibitor therapy. This is a frequently tested trap: tetrabenazine treats chorea but can kill if given to a depressed patient without screening.

3. Predictive genetic testing requires more than informed consent. NCLEX may present a scenario where an at-risk patient wants genetic testing. The correct nursing action is to ensure referral to a certified genetic counselor for pre-test counseling — not simply to obtain informed consent and draw the sample. Post-test counseling is also required, regardless of whether the result is positive or negative.

4. Chorea worsens with anxiety and stress — reduce stimulation. If an NCLEX stem describes a patient with increased involuntary movements in a noisy environment or after an upsetting conversation, the correct intervention is to reduce environmental stimulation — quiet room, calm demeanor, minimize interruptions. This is both assessment knowledge and an intervention.

5. Caloric needs are extremely high. HD patients may need 3,000–5,000 kcal/day due to the metabolic cost of constant choreiform movement. Weight loss is a serious complication and a nursing priority. NCLEX may ask which diet is most appropriate for an HD patient — the answer is high-calorie, high-protein, nutrient-dense, with modified texture as needed for dysphagia.

6. Juvenile HD is more rigid than choreic. If NCLEX presents a young patient (under 20) with an affected parent and describes rigidity, seizures, and behavioral changes rather than chorea, consider juvenile HD (Westphal variant). The clinical picture is inverted — rigidity dominates, and paternal inheritance is more commonly associated with anticipation.

7. Aspiration precautions: chin tuck, upright positioning, thickened liquids. In a patient with HD and dysphagia, the nurse should position the patient upright at 90° for meals, teach the chin-tuck maneuver, implement SLP-recommended liquid thickening, supervise all meals, and not leave the patient alone while eating. NCLEX may ask which action is most important — aspiration prevention takes priority.

8. PEG tube timing requires decisional capacity — plan early. PEG tube insertion should be discussed and decided while the patient retains decisional capacity, not as an emergency measure after they have lost it. The same principle applies to all advance directives in progressive neurological disease. Nurses should proactively facilitate these conversations in early-stage HD.

9. UHDRS is the primary assessment tool — know its four domains. Motor, cognitive, behavioral, and functional capacity. The Total Functional Capacity (TFC) subscale correlates with disease stage and guides prognosis and care planning decisions. NCLEX questions about HD assessment tools point to UHDRS.

10. Caregiver burden is a nursing diagnosis priority. HD caregivers face a 10–30 year caregiving commitment with progressive patient dependence. Caregiver strain, social isolation, financial stress, and anticipatory grief are real nursing priorities. Including the caregiver in your plan of care is not secondary — it is essential to sustaining the patient’s care.

Nursing diagnoses for Huntington’s disease

Listed in priority order:

1. Risk for injury related to choreiform movements, impaired balance, and falls risk — highest priority due to immediate safety threat.
2. Impaired swallowing related to pharyngeal dysfunction and incoordination secondary to neurodegeneration — aspiration risk makes this a life-safety priority.
3. Imbalanced nutrition: less than body requirements related to hypermetabolism, dysphagia, and decreased self-feeding ability.
4. Risk for suicide related to psychiatric symptoms, elevated HD-associated suicide risk, and potential tetrabenazine use — requires active assessment and safety planning.
5. Chronic sorrow related to progressive loss of physical and cognitive function, altered roles, and anticipatory grief — applies to patient and family.
6. Impaired verbal communication related to dysarthria and cognitive decline secondary to neurodegeneration.
7. Caregiver role strain related to prolonged caregiving demands, progressive disease trajectory, and patient dependence — caregiver health directly affects patient safety.
8. Decisional conflict related to genetic testing decisions for at-risk family members and end-of-life care planning.

Related neurological nursing references

• Parkinson’s disease nursing — compare HD chorea (hyperkinetic, VMAT2 depletion treats it) with PD rigidity and tremor (dopamine deficiency, levodopa replaces it)
• ALS nursing reference — compare bulbar dysfunction and PEG timing; both HD and ALS require early advance care planning while decisional capacity is intact
• Multiple sclerosis nursing — compare relapsing-remitting vs progressive neurological decline; HD is uniformly progressive
• Alzheimer’s disease nursing — compare dementia patterns: HD affects executive function first (subcortical); Alzheimer’s affects episodic memory first (hippocampal/cortical)
• Myasthenia gravis nursing reference — compare neuromuscular conditions; MG is autoimmune and potentially reversible, HD is genetic and uniformly progressive
• Seizure nursing — seizures occur in HD, particularly in juvenile HD; know seizure precautions and management
• Head-to-toe assessment — systematic assessment framework for comprehensive HD evaluation
• Glasgow Coma Scale — use to detect acute changes in consciousness or cognition superimposed on HD baseline